Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data
Hematological Oncology · 2023-10 · 41 (4) · 663-673
DOI: 10.1002/hon.3174 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 22.05.2023. Verfasst von Elif Birtas Atesoglu und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, Antibodies, Bispecific, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Glofitamab is a CD3xCD20 bi‐specific antibody with two fragments directed to the CD20 antigen and a single CD3‐binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B‐cell lymphoma. However, the real‐world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B‐cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty‐three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first‐line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow‐up time was 5.7 months. In efficacy‐evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression‐free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment‐responsive patients progressed during the study period, and their estimated 1‐year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab‐related febrile neutropenia. This is the largest real‐world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey.
- Division of Hematology, Anadolu Medical Center, Kocaeli, Turkey.
- Division of Hematology, Acibadem Atakent Hospital, Istanbul, Turkey.
- Department of Internal Medicine, Division of Hematology, Ankara University Medical Faculty, Ankara, Turkey.
- Department of Internal Medicine, Division of Hematology, Uludag University Medical Faculty, Bursa, Turkey.
- Division of Hematology, Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara, Turkey.
ORCID-Profile: Tayfur Toptas, Orhan Kemal Yuce, Volkan Karakus, Muzaffer Keklik, Burhan Ferhanoglu
Zitieren
APA
Birtas Atesoglu, E., Gulbas, Z., Uzay, A., Ozcan, M., Ozkalemkas, F., Dal, M. S., Kalyon, H., Akay, O. M., Deveci, B., Bekoz, H., Sevindik, O. G., Toptas, T., Yilmaz, F., Koyun, D., Alkis, N., Alacacioglu, I., Sonmez, M., Yavasoglu, I., Tombak, A., …, & Ferhanoglu, B. (2023). Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data. Hematological Oncology, 41(4), 663-673. https://doi.org/10.1002/hon.3174
Vancouver
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, et al. Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data. Hematological Oncology. 2023;41(4):663-673. doi:10.1002/hon.3174
BibTeX
@article{BirtasAtesoglu2023,
author = {Birtas Atesoglu, Elif and Gulbas, Zafer and Uzay, Ant and Ozcan, Muhit and Ozkalemkas, Fahir and Dal, Mehmet Sinan and Kalyon, Hakan and Akay, Olga Meltem and Deveci, Burak and Bekoz, Huseyin and Sevindik, Omur Gokmen and Toptas, Tayfur and Yilmaz, Fergun and Koyun, Derya and Alkis, Nihan and Alacacioglu, Inci and Sonmez, Mehmet and Yavasoglu, Irfan and Tombak, Anil and Mehtap, Ozgur and Kurnaz, Fatih and Yuce, Orhan Kemal and Karakus, Volkan and Turgut, Mehmet and Kurekci, Derya Deniz and Ayer, Mesut and Keklik, Muzaffer and Buyuktas, Deram and Ozbalak, Murat and Ferhanoglu, Burhan},
title = {Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {4},
pages = {663--673},
doi = {10.1002/hon.3174}
}
EUVIMED